Non-opioid pain therapies are entering an unprecedented era, marked by the landmark FDA approval of Vertex’s Journavx and a ...

On January 30, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid ...

The U.S. Food and Drug Administration (FDA) has approved Journavx, the first opioid-free prescription drug for moderate to ...

The intriguing phenomenon of pain suppression was observed by Henry Beecher among soldiers during WWII. Pain, often deemed an ...

The FDA approved the first drug in its class that targets moderate to severe acute pain in adults, without being addictive ...

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

"We have the opportunity to change the paradigm of acute pain management and establish a new standard of care,” Kewalramani said. The most common reactions study participants experienced after ...

The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller to win FDA approval in more than 20 years.

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...

A new opioid-free pain medication was approved by the FDA on Thursday, marking a non-addictive alternative for patients.